Patent Issued for Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies (USPTO 11945865).
In: Immunotherapy Weekly, 2024-04-23, S. 2607-2607
serialPeriodical
Zugriff:
A patent has been issued for the blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies. The patent describes an engineered immune cell that includes a nucleic acid encoding a target-binding molecule linked to a localizing domain, as well as a nucleic acid encoding a chimeric antigen receptor (CAR). The CAR includes intracellular signaling domains and an antibody that specifically binds to CD7. The invention aims to provide new therapeutic options for patients with T-cell malignancies, as current treatments are not satisfactory. [Extracted from the article]
Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Patent Issued for Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies (USPTO 11945865).
|
---|---|
Zeitschrift: | Immunotherapy Weekly, 2024-04-23, S. 2607-2607 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1090-8625 (print) |
Schlagwort: |
|
Sonstiges: |
|